Fibrocystic Breast Disease (FCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Fibrocystic breast disease (FCD), a prevalent non-cancerous condition affecting many women globally, falls under benign breast diseases. These conditions encompass non-malignant abnormalities such as tumors, trauma, mastalgia, and nipple discharge. The development of benign breast disease is closely associated with the use of estrogen and anti-estrogen therapies in women. The process of mammary gland development, maturation, and differentiation is influenced by hormonal and growth factor changes, which impact the stromal and epithelial cells. During the late proliferative phase, the glandular tissue may progress to hyperplastic stages like sclerosing adenosis or lobular hyperplasia. Hyperplasia, particularly when associated with a 2% prevalence of Ki67 cells, indicates a twofold increased risk of developing breast cancer. Proliferative lesions exhibit a 1.3 to 1.9 times higher likelihood of malignancy in both breasts. Consequently, any increase in pleomorphic calcifications observed on mammograms should prompt a follow-up regime with intervals of six months. In cases with multiple small lumps unsuitable for surgical removal, the initial treatment approach for fibrocystic breast disease typically focuses on managing the associated symptoms. Mastectomy is commonly employed when necessary. It is most common between the ages of 30 and 50.
Thelansis’s “Fibrocystic Breast Disease (FCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fibrocystic Breast Disease (FCD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Fibrocystic Breast Disease (FCD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Fibrocystic Breast Disease (FCD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment